A novel bispecific antibody CVL006 superior to AK112 for dual targeting of PD-L1 and VEGF in cancer therapy Statement of Significance This project developed CVL006, a PD-L1/VEGF bispecific antibody combining an anti-PD-L1 VHH domain with an anti-VEGF IgG1. Precli

Antibody Therapeutics (IF=4.5, Oxford University Press) ⚡ A novel bispecific antibody CVL006 superior to AK112 for dual targeting of PD-L1 and VEGF in cancer therapy
academic.oup.com/abt/article/...
#bispecific #bispecificantibody #bispecificantibodies #bsab #VEGF #AK112